These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 32116055)

  • 1. How do we improve histone deacetylase inhibitor drug discovery?
    Hamze A
    Expert Opin Drug Discov; 2020 May; 15(5):527-529. PubMed ID: 32116055
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging approaches for histone deacetylase inhibitor drug discovery.
    Zwergel C; Valente S; Jacob C; Mai A
    Expert Opin Drug Discov; 2015 Jun; 10(6):599-613. PubMed ID: 25895649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How could histone deacetylase activators be useful leads in the search for new therapeutics?
    Bourguet E; Naassila M
    Future Med Chem; 2019 Jun; 11(11):1241-1243. PubMed ID: 31161790
    [No Abstract]   [Full Text] [Related]  

  • 4. Histone deacetylase inhibitor based prodrugs.
    Fan W; Zhang L; Jiang Q; Song W; Yan F; Zhang L
    Eur J Med Chem; 2020 Oct; 203():112628. PubMed ID: 32679451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitors.
    Liao D
    Drug Discov Today Technol; 2015 Nov; 18():24-8. PubMed ID: 26723889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving understanding of chromatin regulatory proteins and potential implications for drug discovery.
    Rafehi H; Khan AW; El-Osta A
    Expert Rev Proteomics; 2016; 13(4):435-45. PubMed ID: 26923902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC).
    Chotitumnavee J; Yamashita Y; Takahashi Y; Takada Y; Iida T; Oba M; Itoh Y; Suzuki T
    Chem Commun (Camb); 2022 Apr; 58(29):4635-4638. PubMed ID: 35311871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Label-free in situ monitoring of histone deacetylase drug target engagement by matrix-assisted laser desorption ionization-mass spectrometry biotyping and imaging.
    Munteanu B; Meyer B; von Reitzenstein C; Burgermeister E; Bog S; Pahl A; Ebert MP; Hopf C
    Anal Chem; 2014 May; 86(10):4642-7. PubMed ID: 24559101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of selective histone deacetylase inhibitors: rethinking classical pharmacophore.
    Melesina J; Praetorius L; Simoben CV; Robaa D; Sippl W
    Future Med Chem; 2018 Jul; 10(13):1537-1540. PubMed ID: 29966452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylases: Targets for antifungal drug development.
    Kmetzsch L
    Virulence; 2015; 6(6):535-6. PubMed ID: 26151486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inside HDAC with HDAC inhibitors.
    Bertrand P
    Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?
    Shen S; Kozikowski AP
    ChemMedChem; 2016 Jan; 11(1):15-21. PubMed ID: 26603496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of selective histone deacetylase 3 inhibition.
    Zhang L; Chen Y; Jiang Q; Song W; Zhang L
    Eur J Med Chem; 2019 Jan; 162():534-542. PubMed ID: 30472601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?
    De Simone A; Milelli A
    ChemMedChem; 2019 Jun; 14(11):1067-1073. PubMed ID: 30958639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
    Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW
    Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting autophagy for the therapeutic application of histone deacetylase inhibitors in ischemia/reperfusion heart injury.
    Zhang Y; Ren J
    Circulation; 2014 Mar; 129(10):1088-91. PubMed ID: 24396040
    [No Abstract]   [Full Text] [Related]  

  • 17. Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
    Kalin JH; Bergman JA
    J Med Chem; 2013 Aug; 56(16):6297-313. PubMed ID: 23627282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies in developing promising histone deacetylase inhibitors.
    Zhang L; Fang H; Xu W
    Med Res Rev; 2010 Jul; 30(4):585-602. PubMed ID: 19634125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AS1387392, a novel immunosuppressive cyclic tetrapeptide compound with inhibitory activity against mammalian histone deacetylase.
    Sasamura S; Sakamoto K; Takagaki S; Yamada T; Takase S; Mori H; Fujii T; Hino M; Hashimoto M
    J Antibiot (Tokyo); 2010 Nov; 63(11):633-6. PubMed ID: 20588300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.